BAMLET administration into the stomach or in the drinking water markedly reduced colon cancer development in susceptible mice. The effect was quantified as a reduction in tumor number and tumor size after 2 weeks. Long-term effects were also found in mice that had been treated for 27 weeks, which survived longer than untreated controls, where the disease developed faster. BAMLET was taken up by tumour tissue and was shown to lower the cellular content of several cancer markers. Strikingly, cancer gene expression was inhibited in the treatment group, suggesting a pronounced effect and a return towards health.

Colon cancer is the third most deadly and fourth most commonly diagnosed cancer in world. The Apc^Min/+model mimics human disease, especially familial polyposis where APC mutations increase colon cancer susceptibility. The results suggest that local BAMLET treatment may be effective against colon cancer also in man, with a therapeutic and prophylactic potential. Clinical studies will be required to more precisely define the clinical potential of BAMLET therapy in colon cancer.  

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-10-2020 10:31 CET.

For more information, please contact

 Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49

catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57

mats.persson@hamletpharma.com 

About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine a-lactalbumin and oleic acid. Research on mice suggest that local BAMLET treatment may be effective against colon cancer in man.

This information is insider information that Hamlet Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact persons set out above, on October 6, 2020.